| Literature DB >> 27367858 |
Kumutha Malar Vellasamy1, Vanitha Mariappan1, Esaki M Shankar1,2,3, Jamuna Vadivelu1.
Abstract
BACKGROUND: Burkholderia pseudomallei, the causative agent of melioidosis poses a serious threat to humankind. B. pseudomallei secretes numerous virulence proteins that alter host cell functions to escape from intracellular immune sensors. However, the events underlying disease pathogenesis are poorly understood.Entities:
Mesh:
Year: 2016 PMID: 27367858 PMCID: PMC4930195 DOI: 10.1371/journal.pntd.0004730
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Primer sequences of the genes used for validation of microarray results using qRT-PCR.
| Primer | Sequence 5’– 3’ | Amplicon size (bp) |
|---|---|---|
| CAC CTT CAC CGT TCC AGT TT | 102 | |
| GAT GAG ATT GGC ATG GCT TT | ||
| TGT TGC CAT CAA TGA CCC CTT | 102 | |
| CTC CAC GAC GTA CTC AGC G | ||
| CAG AAG GAC TAC CGA GCT TAC T | 153 | |
| CCA ATC CCC AAT GAC TGC TAC | ||
| CAA GGC GGG GCA GTT ACT C | 118 | |
| TTT CTT GGT CAA GTC AGC AGG | ||
| TCT GCA TCT CTT CGA CTA CTC A | 130 | |
| GTA GAG CAG GAC GCT TTT GTT | ||
| GCG TGG TCA TGT ACC ATC AG | 176 | |
| AGG TGT TGT CAG CTC TGT TTC | ||
| CCT GAA GGC CCC TGA TAA GAA | 196 | |
| GCT GGA CTG ATT GAG GGT GC | ||
| TGG ATG CTC TGT ACG GGA AG | 110 | |
| CCA GGC TGG TGT GAA ACT GAA | ||
| ATC CTC CTC AGT AAG TGG GGT | 101 | |
| CTT GGC AAC TCC CGA AAG C | ||
| ACG TGT GAG AAC GTG GAC TG | 151 | |
| CAC ATT CAT TGC GGT AGG TTT TC |
Mean percentage of invasion (%) with standard deviation MOI 1:10, 1:100 and 1:200.
| Hours | % Invasion (MOI 1:10) | % Invasion (MOI 1:100) | % Invasion (MOI 1:200) |
|---|---|---|---|
| 0.000125±0.00004 | 0.000168±0.00002 | 0.0002±0.00011 | |
| 0.00232±0.00100 | 0.00322±0.00085 | 0.0048±0.00093 | |
| 0.385±0.01400 | 0.399±0.01400 | 0.535±0.01200 | |
| 1.725±0.05500 | 1.888±0.02300 | 1.987±0.09900 | |
| 3.15±0.020000 | 3.28±0.09000 | 3.65±0.05200 | |
| 2.08±0.070000 | 2.00±0.05000 | 2.20±0.05000 | |
| 1.83±0.20000 | 1.75±0.15000 | 1.82±0.07500 |
Fig 1Intracellular survival and replication assay.
Intracellular survival and replication of B. pseudomallei in A549 cell lines were assayed at different time-points (1, 2, 3, 6, 12, 18, 24 h) following 2 hours post-infection with MOI of 1:10, 1:100 and 1:200. At each time-point, the cells were lysed and colony-forming units (CFU) per milliliter of bacteria recovered were determined. Values indicate mean±standard error of 3 independent experiments assayed in triplicate.
Fig 2Differential expression of genes under the BCMS and CCMS conditions.
(A) Number of genes that were significantly (p<0.05; fold change ≥2) up-regulated and down-regulated. (B) Venn diagram of the number of genes commonly regulated both by the BCMS and CCMS conditions, and the number of genes regulated exclusively by each of the conditions.
KEGG pathways significantly regulated by live B. pseudomallei bacteria and its secretory proteins (using GeneTrail and KEGG pathway mapper).
| Pathway regulation | KEGG pathway | BCMS | CCMS | ||
|---|---|---|---|---|---|
| p-value | Genes involved | p-value | Genes involved | ||
| Starch and sucrose metabolism | 1.87e-4 | G6PC2; UGT1A7; UGT1A9; UGT1A10 | 5.47e-3 | G6PC2; UGT1A7; UGT1A9 | |
| Ascorbate and aldarate metabolism | 3.68e-4 | UGT1A7; UGT1A9; UGT1A10; | 1.34e-2 | UGT1A7; UGT1A9 | |
| Pentose and glucuronate interconversions | 5.11e-4 | UGT1A7; UGT1A9; UGT1A10; | 1.65e-2 | UGT1A7; UGT1A9 | |
| Neutrophin signalling pathway | 4.82e-3 | AKT2; BCL2; NTRK3; SHC1 | 1.52e-3 | AKT2; BCL2; NTRK3; SHC1; AKT3 | |
| Insulin signalling pathway | 6.49e-3 | AKT2; G6PC2; PDE3B; SHC1 | 2.89e-4 | AKT2; G6PC2; PDE3B; SHC1; SOCS2; AKT3 | |
| Metabolism of xenobiotics by cytochrome P450 | 6.84e-3 | UGT1A10; UGT1A7; UGT1A9 | - | - | |
| TGF-β signalling pathway | 1.12e-2 | BMP2; BMP5; FST | 1.99e-2 | BMP2; BMP5; FST | |
| Focal adhesion | 2.38e-2 | AKT2; BCL2; COL4A1; SHC1 | 1.12e-2 | AKT2; BCL2; COL4A1; SHC1; AKT3 | |
| Cell adhesion molecules (CAMs) | 3.78e-2 | CDH4; NRCAM; VCAN | 1.30e-2 | CDH4; NRCAM; VCAN; JAM3; | |
| Hedgehog signalling pathway | 3.81e-2 | BMP2; BMP5 | 6.38e-3 | BMP2; BMP5; ZIC2 | |
| ErbB signalling pathway | - | - | 2.11e-2 | AKT2; AKT3; SHC1 | |
| Chemokine signalling pathway | - | - | 3.89e-2 | AKT2; AKT3; DOCK2; SHC1 | |
| mTOR signalling pathway | - | - | 4.88e-2 | AKT2; AKT3 | |
| Apoptosis | - | - | 2.17e-2 | AKT2 AKT3 BCL2 | |
| Fc gamma R-mediated phagocytosis | - | - | 3.79e-3 | AKT2; AKT3; DOCK2; PRKCE | |
| Adipocytokine signalling pathway | - | - | 1.05e-2 | AKT2; AKT3; G6PC2 | |
| Fc epsilon RI signalling pathway | - | - | 1.63e-2 | AKT2; AKT3; PRKCE | |
| JAK-STAT signalling pathway | - | - | 2.06e-2 | AKT2; AKT3; IL11; SOCS2 | |
| Tight junction | - | - | 2.00e-3 | AKT2; AKT3; EPB41L2; JAM3; PRKCE | |
| Complement and coagulation cascades | 2.87e-3 | C3; C4BPB; C5; CFB; CFH; F3 | 7.70e-4 | C3; C4BPB; C5; CFB; CFH; F3; C1S; | |
| Drug metabolism–cytochrome P450 | 3.82e-3 | ALDH1A3; AOX1; GSTM2; GSTM3; MAOA; UGT2B11 | 5.35e-3 | ALDH1A3; AOX1; GSTM2; GSTM3; MAOA; UGT2B11 | |
| Arginine and proline metabolism | 4.92e-3 | ASS1; CKB; GATM; MAOA; GLS; | 2.78e-2 | ASS1; CKB; GATM; MAOA | |
| Nicotinate and nicotinamide metabolism | 1.28e-2 | AOX1; CD38; NNT | 1.54e-2 | AOX1; CD38; NNT | |
| Glutathione metabolism | 1.94e-2 | ANPEP; GPX2; GSTM2; GSTM3 | 2.43e-2 | ANPEP; GPX2; GSTM2; GSTM3 | |
| Alanine, aspartate and glutamate metabolism | 2.78e-2 | ADSSL1; ASS1; GLS | - | - | |
| Lysosome | 3.89e-2 | CTSB; CTSF; GAA; HYAL1; IDUA; MAN2B1 | 1.75e-2 | CTSB; CTSF; GAA; HYAL1; MAN2B1; CTSH; CTSS | |
| Phagosome | 4.49e-2 | C3; CD14; HLA-DMA; ITGB2; OLR1; SCARB1; TUBB2B | 8.14e-3 | C3; CD14; HLA-DMA; ITGB2; OLR1; SCARB1; TUBB2B; CTSS; THBS1 | |
| Antigen processing and presentation | - | - | 7.38e-3 | CTSB; CTSS; HLA-DMA; HSPA2; KIR2DL1; KLRC3 | |
| ECM-receptor interaction | - | - | 1.05e-2 | COL5A2; ITGB4; LAMB2; LAMB3; LAMC3; THBS1 | |
| PPAR signalling pathway | - | - | 1.80e-2 | CPT1C; FADS2; OLR1; SLC27A1; SLC27A2 | |
| Histidine metabolism | - | - | 2.56e-2 | ALDH1A3; AMDHD1; MAOA | |
KEGG pathways significantly regulated by live B. pseudomallei and secretory proteins (using GATHER with the activated Infer from Network component).
| Condition | Regulation | KEGG pathway | Number of genes | p-value | Bayes factor |
|---|---|---|---|---|---|
| Up-regulated | Apotosis | 38 | 0.003 | 23 | |
| MAPK signalling pathway | 45 | 0.05 | 3 | ||
| Down-regulated | Cytokine-cytokine receptor interactions | 111 | 0.001 | 38 | |
| Jak-STAT signalling pathway | 59 | 0.01 | 11 | ||
| Toll-like receptor signalling | 40 | 0.02 | 8 | ||
| Up-regulated | MAPK signalling pathway | 46 | 0.05 | 3 | |
| Down-regulated | Cytokine-cytokine receptor interactions | 110 | 0.001 | 35 | |
| Jak-STAT signalling pathway | 59 | 0.02 | 10 | ||
| Toll-like receptor signalling | 40 | 0.02 | 8 |
Fig 3Heat map analysis of host (A549, human lung epithelial cell) transcriptional responses to early exposure with live B. pseudomallei and its secretory proteins.
Hierarchical clustering of the expression profile is grouped according to functional categories. Heat maps indicate the fold change in A549 cells gene expression >2-fold (red) or <2-fold (green). Genes with no expression change are colored in black.
Validated genes regulated in response to live B. pseudomallei and its secreted proteins.
| Symbol | Description | BCMS | CCMS | ||
|---|---|---|---|---|---|
| Array | qRT-PCR | Array | qRT-PCR | ||
| Glucose-6-phosphatase, catalytic, 2 | 13.24 | 16.33 | 6.57 | 11.26 | |
| Carboxylesterase 1 | -14.14 | -10.10 | -24.44 | -18.74 | |
| Chemokine (C-X-C motif) receptor 7 | 5.78 | 8.34 | 6.23 | 8.99 | |
| Layilin | -13.80 | -15.2 | -10.65 | -12.59 | |
| Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 | -10.17 | -9.67 | -12.07 | -11.73 | |
| PYD and CARD domain containing | -62.52 | -79.98 | -58.18 | -85.77 | |
| FXYD domain containing ion transport regulator 2 | 41.36 | 65.13 | 41.63 | 68.52 | |
| Follistatin | 34.02 | 35.11 | 33.22 | 35.00 | |